Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology

Open Access 24-04-2024 | Rituximab | Original Communication

Rituximab in non-systemic vasculitic neuropathy: a single-center experience

Authors: Felix Kohle, Gilbert Wunderlich, Gereon R. Fink, Michael Schroeter, Helmar C. Lehmann, Christian Schneider

Published in: Journal of Neurology

Login to get access

Abstract

Objectives

This case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy (NSVN) treated with the anti-CD20 agent rituximab.

Methods

Clinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients with pathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis. Follow-up data for at least 12 months and up to five years is provided. Outcome of the patients was assessed using the MRC-Sum Score, Prineas Score and Neurological Symptom Score.

Results

Two of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated under rituximab induction. Rituximab was well tolerated in all patients.

Discussion

Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatment switch due to side effects of corticosteroids or cyclophosphamide.
Literature
1.
Kohle F, Dalakas MC, Lehmann HC (2023) Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy? Ther Adv Neurol Disord 16:17562864221137128CrossRefPubMedPubMedCentral
2.
3.
Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, Léger JM, Notermans NC, Pollard JD, Said G, Sobue G, Vrancken AF, Kissel JT (2010) Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 15:176–184CrossRefPubMed
4.
Schneider C, Wassermann MK, Fink GR, Lehmann HC (2022) Single-center experience of induction therapy in non-systemic vasculitic neuropathy. Neurol Res Pract 4:32CrossRefPubMedPubMedCentral
5.
Üçeyler N, Geng A, Reiners K, Toyka KV, Sommer C (2015) Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol 262:2092–2100CrossRefPubMed
6.
Kleyweg RP, Van Der Meché FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 14:1103–1109CrossRefPubMed
7.
8.
Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O’Brien PC, Grina LA, Palumbo PJ, Swanson CJ (1980) Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 8:590–596CrossRefPubMed
9.
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, Maurier F, Decaux O, Ninet J, Gobert P, Quémeneur T, Blanchard-Delaunay C, Godmer P, Puéchal X, Carron PL, Hatron PY, Limal N, Hamidou M, Ducret M, Daugas E, Papo T, Bonnotte B, Mahr A, Ravaud P, Mouthon L (2014) Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371:1771–1780CrossRefPubMed
10.
Schneider C, Wunderlich G, Bleistein J, Fink GR, Deckert M, Brunn A, Lehmann HC (2017) Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. J Neurol Neurosurg Psychiatry 88:756–760CrossRefPubMed
11.
12.
Catron DM, Rusch LK, Hataye J, Itano AA, Jenkins MK (2006) CD4+ T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells. J Exp Med 203:1045–1054CrossRefPubMedPubMedCentral
13.
García Nores GD, Ly CL, Cuzzone DA, Kataru RP, Hespe GE, Torrisi JS, Huang JJ, Gardenier JC, Savetsky IL, Nitti MD, Yu JZ, Rehal S, Mehrara BJ (2018) CD4+ T cells are activated in regional lymph nodes and migrate to skin to initiate lymphedema. Nat Commun 9:1970CrossRefPubMedPubMedCentral
14.
Takahashi M, Koike H, Ikeda S, Kawagashira Y, Iijima M, Hashizume A, Katsuno M, Sobue G (2017) Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurol Neuroimmunol Neuroinflamm 4:e407CrossRefPubMedPubMedCentral
15.
Margoni M, Preziosa P, Filippi M, Rocca MA (2022) Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol 269:1316–1334CrossRefPubMed
16.
Witt AM, Kodal LS, Pedersen BS, Lund EL, Dysgaard T (2023) Misinterpretation of non-systemic vasculitic neuropathy results in delayed treatment. Ugeskr Laeger 185(18):V10220665PubMed
17.
Lima K, Tavee J, Dua A (2021) Combination rituximab and intravenous immunoglobulin for treatment of refractory vasculitic neuropathy: a case series. Rheumatology 60:4884–4887CrossRefPubMed
18.
Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2022) Rituximab for the treatment of multiple sclerosis: a review. J Neurol 269:159–183CrossRefPubMed
19.
Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A (2019) Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J Neurol 266:57–67CrossRefPubMed
20.
Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR (2008) Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol 141:135–148CrossRefPubMed
21.
Perumal JS, Kister I, Howard J, Herbert J (2015) Disease exacerbation after rituximab induction in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e61CrossRefPubMedPubMedCentral
22.
Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D (2015) Cryoglobulinemia Vasculitis. Am J Med 128:950–955CrossRefPubMed
Metadata
Title
Rituximab in non-systemic vasculitic neuropathy: a single-center experience
Authors
Felix Kohle
Gilbert Wunderlich
Gereon R. Fink
Michael Schroeter
Helmar C. Lehmann
Christian Schneider
Publication date
24-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-024-12378-1